1616428-23-9 ((Luxeptinib)

Luxeptinib;CG806;TQ6PBX1JU0;CG026806;Luxeptinib [USAN];US9758508, Compound 7;GTPL11671;BDBM340031;example 7 [US9758508B2];NSC791692;WHO 11799;D96116;1-[3-fluoro-4-[7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydroisoindol-4-yl]phenyl]-3-(2,4,6-trifluorophenyl)urea;1-{3-fluoro-4-[7-(5-methyl-1H-imidazol-2- yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]- phenyl}-3-(2,4,6-trifluoro-phenyl)-urea;3-{3-FLUORO-4-[7-(4-METHYL-1H-IMID;CG-806 (Luxeptinib);Pan-FLT3/Pan-BTK Multi-kinase Inhibitor CG-806;FLT3/BTK Inhibitor CG 806;Pan-FLT3/Pan-BTK Inhibitor CG-806;NSC-791692;CHEMBL4594420;CS-0204021;LUXEPTINIB [WHO-DD];LUXEPTINIB [INN];HY-139535;UNII-TQ6PBX1JU0;SCHEMBL17219212;1-(3-fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydroisoindol-4-yl)phenyl)-3-(2,4,6-trifluorophenyl)urea;D12052;CG'806;NSC834160;CG 806;NSC-834160;1616428-23-9;Pan-FLT3/BTK Multi-Kinase Inhibitor CG 806;CG-026806;3-{3-FLUORO-4-[7-(4-METHYL-1H-IMIDAZOL-2-YL)-1-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YL]PHENYL-1-(2,4,6-TRIFLUOROPHENYL)UREA;MS-29200;AKOS040755621;Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(2,4,6-trifluorophenyl)-;example 7 (US9758508B2);32,72,74,76-TETRAFLUORO-14-METHYL-21,23-DIHYDRO-11H-4,6-DIAZA-2(4,7)-ISOINDOLA- 1(2)-IMIDAZOLA-3(1,4),7(1)-DIBENZENAHEPTAPHANE-2,35-DIONE;Urea, N-[4-[2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl]-3-fluorophenyl]-N'-(2,4,6-trifluorophenyl)-;32,72,74,76-TETRAFLUORO-14-METHYL-21,23-DIHYDRO-11H-4,6-DIAZA-2(4,7)-ISOINDOLA-1(2)-IMIDAZOLA-3(1,4),7(1)-DIBENZENAHEPTAPHANE-2,35-DIONE;GLXC-25679;DA-65120;Luxeptinib (USAN);

MWHHJYUHCZWSLS-UHFFFAOYSA-N

1S/C25H17F4N5O2/c1-11-9-30-23(32-11)16-5-4-14(17-10-31-24(35)21(16)17)15-3-2-13(8-18(15)27)33-25(36)34-22-19(28)6-12(26)7-20(22)29/h2-9H,10H2,1H3,(H,30,32)(H,31,35)(H2,33,34,36)

FC1C=C(C=CC=1C1=CC=C(C2=NC=C(C)N2)C2C(NCC=21)=O)NC(NC1C(=CC(=CC=1F)F)F)=O